Christian M. Lange

ORCID: 0000-0001-9983-5136
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Liver Disease Diagnosis and Treatment
  • Liver Disease and Transplantation
  • Hepatitis C virus research
  • Hepatitis B Virus Studies
  • Vitamin D Research Studies
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Monoclonal and Polyclonal Antibodies Research
  • Amoebic Infections and Treatments
  • Obstructive Sleep Apnea Research
  • Drug-Induced Hepatotoxicity and Protection
  • Organ Transplantation Techniques and Outcomes
  • Electrolyte and hormonal disorders
  • Neuroscience of respiration and sleep
  • Systemic Lupus Erythematosus Research
  • Microscopic Colitis
  • Hepatitis Viruses Studies and Epidemiology
  • Cancer Mechanisms and Therapy
  • Immune Cell Function and Interaction
  • Inflammation biomarkers and pathways
  • HIV-related health complications and treatments
  • Infectious Encephalopathies and Encephalitis
  • Gut microbiota and health
  • Extracellular vesicles in disease
  • Advanced Glycation End Products research
  • Amyotrophic Lateral Sclerosis Research

München Klinik
2023-2025

LMU Klinikum
2022-2025

Ludwig-Maximilians-Universität München
2022-2025

University of Lübeck
2013-2024

University Hospital Schleswig-Holstein
2013-2024

University of Duisburg-Essen
2021-2023

Essen University Hospital
2020-2023

University Hospital of Bern
2023

University of Bern
2023

Fortis Healthcare
2022

Peripheral percutaneous transluminal angioplasty is fraught with a substantial risk of restenosis and reintervention. A drug-eluting balloon (DEB) based on novel coating was compared uncoated balloons in patients undergoing femoro-popliteal angioplasty.Patients symptomatic atherosclerotic disease were randomized to paclitaxel-coated IN.PACT Pacific or balloons. The primary end point late lumen loss at 6 months assessed by blinded angiographic corelab quantitative analyses. Secondary points...

10.1161/circinterventions.112.971630 article EN Circulation Cardiovascular Interventions 2012-11-29

Vitamin D is an important immune modulator that plays emerging role in inflammatory and metabolic liver diseases, including infection with hepatitis C virus (HCV). In contrast, the relationship between vitamin metabolism chronic B (CHB) less well characterized. Therefore, we quantified 25(OH)D3 serum levels a cohort of 203 treatment-naïve patients (HBV) tested for their association clinical parameters CHB. Of patients, 69 (34%), 95 (47%), 39 (19%) had severe deficiency (25(OH)D3 <10...

10.1002/hep.26488 article EN Hepatology 2013-05-22

Background Lenvatinib is approved as first-line treatment for patients with advanced hepatocellular carcinoma (HCC). The efficacy of lenvatinib in Caucasian real-world insufficiently defined. purpose this study was to evaluate the a multi-center cohort (ELEVATOR) from Germany and Austria. Methods A retrospective data analysis 205 treated systemic at 14 different sites conducted. Overall survival, progression free overall response rate adverse event rates were assessed analyzed. Results...

10.1159/000521746 article EN cc-by Liver Cancer 2022-01-01

Background Vitamin D insufficiency has been associated with the occurrence of various types cancer, but causal relationships remain elusive. We therefore aimed to determine relationship between genetic determinants vitamin serum levels and risk developing hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC). Methodology/Principal Findings Associations CYP2R1, GC, DHCR7 genotypes that are reduced 25-hydroxyvitamin (25[OH]D3) HCV-related HCC development were investigated for 1279...

10.1371/journal.pone.0064053 article EN PLoS ONE 2013-05-29

Background Novel direct-acting antiviral DAA combination therapies tremendously improved sustained virologic response (SVR) rates in patients with chronic HCV infection. SVR is typically accompanied by normalization of liver enzymes, however, hepatic inflammation, i.e. persistently elevated aminotransferase levels may persist despite eradication. Aim: To investigate prevalence and risk factors for ongoing inflammation after two large patient cohorts. Methods This post-hoc analysis was based...

10.1371/journal.pone.0171755 article EN cc-by PLoS ONE 2017-02-14

Background Vitamin D is required to maintain the integrity of intestinal barrier and inhibits inflammatory signaling pathways. Objective deficiency might be involved in cirrhosis-associated systemic inflammation risk hepatic decompensation patients with liver cirrhosis. Methods Outpatients Hepatology Unit University Hospital Frankfurt advanced fibrosis cirrhosis were prospectively enrolled. 25-hydroxyvitamin (25(OH)D3) serum concentrations quantified associated markers / bacterial...

10.1371/journal.pone.0207162 article EN cc-by PLoS ONE 2018-11-08

<b><i>Background and Aims:</i></b> The multikinase inhibitor cabozantinib has been approved for hepatocellular carcinoma (HCC) previously treated with sorafenib. We report safety efficacy data of an international, multicenter, real-life cohort patients advanced HCC cabozantinib. <b><i>Methods:</i></b> Patients who were retrospectively identified across 11 centers in Austria, Switzerland, Germany. Patients’ characteristics, adverse events,...

10.1159/000515490 article EN cc-by-nc Liver Cancer 2021-01-01

Abstract Elevated serum ferritin levels may reflect a systemic inflammatory state as well increased iron storage, both of which contribute to an unfavorable outcome chronic hepatitis C (CHC). We therefore performed comprehensive analysis the role and its genetic determinants in pathogenesis treatment CHC. To this end, at baseline therapy with pegylated interferon-alpha ribavirin or before biopsy were correlated clinical histological features virus (HCV) infection, including necroinflammatory...

10.1002/hep.24787 article EN Hepatology 2011-11-17

Pyogenic liver abscesses (PLA) remain a significant clinical problem. Unfortunately, little is known about current bacterial susceptibility profiles and the incidence of multidrug resistant organisms (MDROs) causing PLA in Western countries. Yet, this crucial information pivotal to guide empirical antibiotic therapy. Aim study was provide detailed characteristics with special focus on underlying pathogens their antibiotics.A retrospective patients diagnosed from 2009 2015 large tertiary...

10.1186/s12879-017-2543-1 article EN cc-by BMC Infectious Diseases 2017-06-26

ABSTRACT Background and Aims Drug‐induced liver injury (DILI) due to metamizole has gained increasing attention. Causality assessment remains a challenge, especially in patients with co‐medications. We therefore aimed further characterise DILI cases. Methods The data of intake from our prospective study on acute potential drug‐related causes were analysed. Diagnosis causality based thorough work‐up long‐term follow‐up. Results was associated 61 324 (prevalence 18.8%). A highly characteristic...

10.1111/liv.70012 article EN cc-by Liver International 2025-02-06

Objective. The aim of the study was to characterize expression TLR2, TLR4 and TLR9 in PMNs patients with granulomatosis polyangiitis (GPA) elucidate role these receptors GPA respect neutrophil activation. Methods. determined on ex vivo whole blood samples (n = 35) healthy controls (HCs) 24). Isolated were stimulated vitro TLR agonists assessed for degranulation, membrane proteinase 3 (mPR3) expression, soluble l-selectin shedding cytokine production (IL-8) five HCs. priming effects TLR2...

10.1093/rheumatology/kes415 article EN Lara D. Veeken 2013-02-12

Abstract Obstructive sleep apnea syndrome (OSAS) and obesity go hand in the majority of patients both are associated with a systemic inflammation, immune disturbance comorbidities such as cardiovascular disease. However, unambiguous impact OSAS on individual inflammatory microenvironment immunological consequences human monocytes has not been distinguished yet. Therefore, aim this study was to investigate related factors by performing flow cytometric whole blood measurements CD14/CD16...

10.1038/s41598-023-49921-5 article EN cc-by Scientific Reports 2024-01-03
Coming Soon ...